10.1371/journal.pone.0090133PLoS ONE93-POLN

Byung Hoon Min

CJ Allegra

Do Hoon Lim

Dong Il Choi

F Levi

GK Geiss

Ho Yeong Lim

I Sohn

Iain Beehuat Tan

IB Tan

In-Gu Do

Insuk Sohn

J Lee

Jae J. Kim

Jae Moon Bae

JB Fan

Jeeyun Lee

JJ Nigro

Joon Haeng Lee

Joon Oh Park

JS Macdonald

Ju-Seog Lee

JY Cho

K Lee

K Yasui

Kakoli Das

KM Clark-Langone

Kyoung-Mee Kim

M Bibikova

Min Gew Choi

Patrick Tan

Poong Lyul Rhee

R Simon

S Folli

S Kim

Se Hoon Park

Sin Ho Jung

Sung Kim

Tae Sung Sohn

Won Ki Kang

Y Hoshida

YJ Bang

Young Suk Park

PubMed

Lee Jeeyun

Sohn Insuk

Do In-Gu

Kim Kyoung-Mee

Park Se Hoon

Park Joon Oh

Park Young Suk

Lim Ho Yeong

Sohn Tae Sung

Bae Jae Moon

Choi Min Gew

Lim Do Hoon

Min Byung Hoon

Lee Joon Haeng

Rhee Poong Lyul

Kim Jae J.

Choi Dong Il

Tan Iain Beehuat

Das Kakoli

Tan Patrick

Jung Sin Ho

Kang Won Ki

Kim Sung

Public Library of Science (PLOS)

Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery

<div><p>Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N = 432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N = 186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N = 216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N = 300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N = 216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence = 3.16, p = 0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio = 1.77, p = 0.0053).</p></div

Jeeyun Lee (145602)

Insuk Sohn (289684)

In-Gu Do (173905)

Kyoung-Mee Kim (145630)

Se Hoon Park (14424)

Joon Oh Park (157701)

Young Suk Park (173931)

Ho Yeong Lim (277134)

Tae Sung Sohn (277132)

Jae Moon Bae (277133)

Min Gew Choi (277131)

Do Hoon Lim (531228)

Byung Hoon Min (531229)

Joon Haeng Lee (531230)

Poong Lyul Rhee (531231)

Jae J. Kim (531232)

Dong Il Choi (439005)

Iain Beehuat Tan (258889)

Kakoli Das (531233)

Patrick Tan (18147)

Sin Ho Jung (531234)

Won Ki Kang (157708)

Sung Kim (59072)

The Francis Crick Institute

Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N=432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N=186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N=216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N=300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N=216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence=3.16, p=0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio=1.77, p=0.0053)

Jae J Kim

Directory of Open Access Journals

PLoS ONE

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery.

Crossref

https://figshare.com/articles/_Nanostring_Based_Multigene_Assay_to_Predict_Recurrence_for_Gastric_Cancer_Patients_after_Surgery_/953111

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery

Abstract

Similar works

Full text

Available Versions

Public Library of Science (PLOS)

The Francis Crick Institute

Directory of Open Access Journals

Crossref

Public Library of Science (PLOS)